Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Featured trial
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

  • 84 views
  • 25 Mar, 2021
  • 1 location
Featured trial
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 184 views
  • 25 Mar, 2021
  • 1 location
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated

infliximab
azathioprine
tumor necrosis factor alpha
hematochezia
endoscopy
  • 0 views
  • 07 Oct, 2022
  • 62 locations
Defining Predictors of RT Response to Vedolizumab in IBD

The overall goal of the study is to develop data that can convincingly guide clinicians on the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need to identify

  • 12 views
  • 07 Oct, 2022
  • 1 location
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative

  • 8 views
  • 03 Jun, 2022
  • 24 locations
Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

This is a pilot study of combination therapy using FMT and vedolizumab for induction of UC. The investigators hypothesize that a combination therapy approach which addresses immune trafficking

enemas
tumor necrosis factor
fecal microbiota transplantation
microbiota
vedolizumab
  • 0 views
  • 04 Oct, 2022
  • 1 location
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

Crohn's disease. Vedolizumab, a novel biologic agent, is a recombinant humanized monoclonal antibody that specifically antagonizes intestine-selective α4β7 integrins on the surface of leukocyte subsets

inflammatory bowel disease
monoclonal antibodies
Accepts healthy volunteers
antibiotics
crohn's disease
  • 0 views
  • 04 Oct, 2022
  • 1 location
LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.

microbiota
vedolizumab
  • 0 views
  • 04 Oct, 2022
  • 1 location
A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication.

  • 0 views
  • 04 Oct, 2022
  • 2 locations
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with

infliximab
azathioprine
endoscopy
immunomodulators
adalimumab
  • 0 views
  • 07 Oct, 2022
  • 41 locations